LONDON, June 30 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) announced that it has opened a new office in Budapest, Hungary.
Dr. Attila Lorinczi will lead this operation. Dr. Lorinczi is a member of the Hungarian Medical Society and the Society of Hungarian Urologists. Dr. Lorinczi has broad experience in the pharmaceutical industry spanning over 13 years, most recently as a clinical operations manager.
“Hungary and the CEE region continue to provide excellent quality data and good patient recruitment rates,” Attila commented. “We expect this to grow further due to the knowledge and expertise of Hungarian investigators and the availability of quality staff.”
“Chiltern continues to expand following our recent opening of an office in Belgium,” explained Lewis Cameron, Chiltern Executive Vice President for Europe. “Central and Eastern Europe continues to be a key focus for our clinical trials and Hungary is an important component of this region. We are delighted to show our continual regional growth in line with our strategy for increased global coverage.”
Company profile
About Chiltern:
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 28 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information is available at www.chiltern.com.
CONTACT: Stuart McGuire, 44 (0) 1753 512 000, fax, 44 (0) 1753 511 116,
stuart.mcguire@chiltern.com, or Mac McElroy, +1-423-968-9533, fax,
+1-423-968-3567, mac.mcelroy@chiltern.com, both of Chiltern International
Ltd.
Web site: http://www.chiltern.com/
